Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Brooks Laboratories's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Brooks Laboratories's Dividend Payout Ratio or its related term are showing as below:
BOM:533543's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.38 * Ranked among companies with meaningful Dividend Payout Ratio only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Brooks Laboratories (BOM:533543) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Brooks Laboratories Dividend Payout Ratio Related Terms
Brooks Laboratories Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:533543 vs ZTS: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's Dividend Payout Ratio falls into.
Brooks Laboratories Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Brooks Laboratories's Dividend Payout Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brooks Laboratories (BOM:533543) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Brooks Laboratories and its competitors. According to the industry distribution chart, Brooks Laboratories ranks #999999 out of 444 companies in the Drug Manufacturers industry.
Is Brooks Laboratories' Dividend Payout Ratio too high?
Brooks Laboratories' current Dividend Payout Ratio is 0.00. Based on the distribution chart, Brooks Laboratories ranks #999999 out of 444 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Brooks Laboratories has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Dividend Payout Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #999999 out of 444 companies for Dividend Payout Ratio. This places Brooks Laboratories in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 444 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹118.16, compared to a current price of ₹64.20 — trading 45.7% below its estimated fair value. The current Dividend Payout Ratio is 0.00. Brooks Laboratories' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹64.20 is trading 45.7% below its estimated GF Value™ of ₹118.16.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
Dividend Payout Ratio: 0.00
GF Value™: ₹118.16 vs. price of ₹64.20 (45.7% below fair value)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
57GF Score
Get the complete analysis for BOM:533543
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
